Now showing items 1-2 of 2

    • Maximum potential cost-savings attributable to generic substitution of antipsychotics 2008 to 2013 

      Husselmann, D.; Joubert, R.; Burger, J.R.; Lubbe, M.S.; Cockeran, M. (Elsevier, 2016)
      Background Schizophrenia is a costly illness to treat, especially during a time of escalating medicine inflation costs, putting a large economic strain on patients, their families and the community. Treatment, however, ...
    • The nature of relapse in schizophrenia 

      Emsley, Robin; Harvey, Brian H.; Chiliza, Bonginkosi; Asmal, Laila (BioMed Central, 2013)
      Background: Multiple relapses characterise the course of illness in most patients with schizophrenia, yet the nature of these episodes has not been extensively researched and clinicians may not always be aware of important ...